Johns Hopkins spin-out GreyBug raises $1.5m in series A whilst announcing new CEO.
GreyBug, a life sciences company focused on developing eye disease treatments, announce both $1.5m series A and a new chief executive (CEO). Michael O’Rourke, an 18-year veteran in ophthalmic leadership and commercialisation and a former member of GreyBug’s scientific advisory board, takes the helm as president and CEO of the Johns Hopkins University spin-out. He…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
